ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Diabetes and endocrinology · Diabetes Care · 2026-08-01

Secondary analysis of the TriMaster crossover trial (309 adults with type 2 diabetes given sitagliptin, canagliflozin and pioglitazone): a routine-features prediction model beat cluster-based allocation for HbA1c reduction (0.27% vs 0.16%); DDRTree showed no association.

Secondary analysisn = 309
Güdemann et al. To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial
Diabetes and endocrinology · Diabetes Care · 2026-02-01

Secondary analysis of GRADE (724 adults with type 2 diabetes on metformin): glucagon measures were not associated with HbA1c ≥7.0%, whereas a 1-SD rise in C-peptide index was associated with 17% lower risk; no clear drug differences on glucagon.

Secondary analysisn = 724
Kahn et al. Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.